Search

Displaying results 1791 - 1800 of 9325 in total
  1. Drug

    Pralatrexate

    go.drugbank.com/drugs/DB06813
    ApprovedInvestigational

    [A246703] As such, pralatrexate is thought to have a better therapeutic window compared to other antifolate analogs due to the novel target of RFC. … Pralatrexate was developed in response due to the inferior responses of patients using the standard therapy for their B-cells counterparts.

  2. Drug

    Pegcetacoplan

    go.drugbank.com/drugs/DB16694
    ApprovedInvestigational

    [L34095] In February 2023, pegcetacoplan for intravitreal use was approved by the FDA for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.[L45354] … [A235000,L34095] Prior to its FDA approval, patients with PNH were typically treated with the C5 inhibiting monoclonal antibody [eculizumab].

  3. Drug

    Trioxsalen

    go.drugbank.com/drugs/DB04571
    ApprovedWithdrawn

    In research it can be conjugated to dyes for confocal microscopy and used to visualize sites of DNA damage.[3] The compound is has been explored for development of antisense oligonucleotides that can be … Like other psoralens it causes photosensitization of the skin.

  4. Drug

    Sulfacytine

    go.drugbank.com/drugs/DB01298
    Approved

    Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. … However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues.

  5. Drug

    Human C1-esterase inhibitor

    go.drugbank.com/drugs/DB06404
    ApprovedInvestigational

    The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways. … The disease is characterized by acute attacks of painful, and in some cases, fatal swelling of several soft tissues or edema, which may last up to five days when untreated.[L16586, L16606]

    Products: CİNRYZE 500 IU/5 ML IV ENJEKSİYONLUK ÇÖZELTİ İÇİN LİYOFİLİZE TOZ VE ÇÖZÜCÜ, 2 ADET
  6. Drug

    Lotilaner

    go.drugbank.com/drugs/DB17992
    ApprovedInvestigationalVet approved

    The active ingredient found in drug products of lotilaner is the S-enantiomer. … [A260746, L47556] Lotilaner consists of two enantiomers: the S-enantiomer is active _in vivo_, while the R-enantiomer is reported to exhibit low biological activity.

  7. Drug

    Cefmenoxime

    go.drugbank.com/drugs/DB00267
    Approved

    It is reported to exhibit high activity against a wide variety of gram-positive and gram-negative bacteria. … Cefmenoxime is a novel broad-spectrum and third-generation cephalosporin antibiotic that is typically used in the treatment of female gynecologic and obstetric infections.

    Synonyms: (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
  8. Drug

    Trichlormethiazide

    go.drugbank.com/drugs/DB01021
    ApprovedVet approved

    A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)

  9. Drug

    Latamoxef

    go.drugbank.com/drugs/DB04570
    Approved

    Latamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins … It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.

  10. Drug

    Ponatinib

    go.drugbank.com/drugs/DB08901
    ApprovedInvestigational

    Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.